Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks - Top-Institutions - MDSpire

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

  • By

  • Howard L. Sofen

  • Ranga Gogineni

  • Tushar Nishandar

  • Jerry Bagel

  • May 9, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai

    New York, New York

    Key Differentiators

    • Dermatology

  • #2

    Oregon Medical Research Center
    Oregon Medical Research Center

    Portland, Oregon

    Key Differentiators

    • Dermatology

Original Source(s)

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

  • by Howard L. Sofen, Ranga Gogineni, Tushar Nishandar, Jerry Bagel

  • May 9, 2026

Related Content

Top 10 Evidence-Based Essentials in Dermatology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice

Rare Skin Reaction Reported With Tirzepatide

A single case report described possible lichen planus pigmentosus inversus following tirzepatide initiation.

Survey on Real-World Interventions and Strategies for Treat-to-Target Approaches in Psoriasis Management in Canada